Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls

Endocrine

Volumn 48, Issue 3, 2015, Pages 848-855

  Zibar, Karin ^a   Blaslov, Kristina ^a   Bulum, Tomislav ^a   Ćuća, Jadranka Knežević ^a   Smirčić Duvnjak, Lea ^a,b  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

C peptide negative; Fibroblast growth factor 21; Healthy controls; Type 1 diabetes mellitus

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; LIPID; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SECRETION; SEX DIFFERENCE; YOUNG ADULT; BLOOD; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY;

ADULT; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84925728502     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0413-9     Document Type: Article

References (29)

1. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, R.A. Owens, J. Gromada, J.T. Brozinick, E.D. Hawkins, V.J. Wroblewski, D.S. Li, F. Mehrbod, S.R. Jaskunas, A.B. Shanafelt, FGF-21 as a novel metabolic regulator. J. Clin. Investig. 115(6), 1627–1635 (2005)
2. M. Mraz, M. Bartlova, Z. Lacinova, D. Michalsky, M. Kasalicky, D. Haluzikova, M. Matoulek, I. Dostalova, V. Humenanska, M. Haluzik, Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. 71(3), 369–375 (2009)
3. W.W. Chen, L. Li, G.Y. Yang, K. Li, X.Y. Qi, W. Zhu, Y. Tang, H. Liu, G. Boden, Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 116(1), 65–68 (2008)
4. A.O. Chavez, M. Molina-Carrion, M.A. Abdul-Ghani, F. Folli, R.A. Defronzo, D. Tripathy, Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32(8), 1542–1546 (2009)
5. W.X. Jian, W.H. Peng, J. Jin, X.R. Chen, W.J. Fang, W.X. Wang, L. Qin, Y. Dong, Q. Su, Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism 61(6), 853–859 (2012)
6. S.Y. An, M.S. Lee, S.A. Yi, E.S. Ha, S.J. Han, H.J. Kim, D.J. Kim, K.W. Lee, Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res. Clin. Pract. 96(2), 196–203 (2012)
7. F.L. Mashili, R.L. Austin, A.S. Deshmukh, T. Fritz, K. Caidahl, K. Bergdahl, J.R. Zierath, A.V. Chibalin, D.E. Moller, A. Kharitonenkov, A. Krook, Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab. Res. Rev. 27(3), 286–297 (2011)
8. T. Reinehr, J. Woelfle, R. Wunsch, C.L. Roth, Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J. Clin. Endocrinol. Metab. 97(6), 2143–2150 (2012)
9. C. Hale, M.M. Chen, S. Stanislaus, N. Chinookoswong, T. Hager, M. Wang, M.M. Veniant, J. Xu, Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153(1), 69–80 (2012)
10. Y. Murata, M. Konishi, N. Itoh, FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology. J. Nutr. Metab. 2011, 981315 (2011)
11. F.M. Fisher, P.C. Chui, P.J. Antonellis, H.A. Bina, A. Kharitonenkov, J.S. Flier, E. Maratos-Flier, Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59(11), 2781–2789 (2010)
12. A. Kharitonenkov, J.D. Dunbar, H.A. Bina, S. Bright, J.S. Moyers, C. Zhang, L. Ding, R. Micanovic, S.F. Mehrbod, M.D. Knierman, J.E. Hale, T. Coskun, A.B. Shanafelt, FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215(1), 1–7 (2008)
13. P. Hojman, M. Pedersen, A.R. Nielsen, R. Krogh-Madsen, C. Yfanti, T. Akerstrom, S. Nielsen, B.K. Pedersen, Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58(12), 2797–2801 (2009)
14. T. Uebanso, Y. Taketani, H. Yamamoto, K. Amo, H. Ominami, H. Arai, Y. Takei, M. Masuda, A. Tanimura, N. Harada, H. Yamanaka-Okumura, E. Takeda, Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS ONE 6(8), e22976 (2011)
15. H. Yu, F. Xia, K.S. Lam, Y. Wang, Y. Bao, J. Zhang, Y. Gu, P. Zhou, J. Lu, W. Jia, A. Xu, Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin. Chem. 57(5), 691–700 (2011)
16. Y. Xiao, A. Xu, L.S. Law, C. Chen, H. Li, X. Li, L. Yang, S. Liu, Z. Zhou, K.S. Lam, Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J. Clin. Endocrinol. Metab. 97(1), E54–E58 (2012)
17. N. Matikainen, M.-R. Taskinen, S. Stennabb, N. Lundbom, A. Hakkarainen, K. Vaaralahti, T. Raivio, Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. Eur. J. Endocrinol. 166, 487–492 (2012)
18. Z. Lin, Q. Gong, C. Wu, L. Yu, X. Pan, S. Lin, X. Li, Dynamic change of serum FGF21 levels in response to glucose challenge in human. J. Clin. Endocrinol. Metab. 97, E1224–E1228 (2012)
19. World Health Organization, Department of Noncommunicable Disease Surveillance: Definition, diagnosis and classification of diabetes and its complications. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva (1999)
20. M. Yang, J. Dong, H. Liu, L. Li, G. Yang, Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS One 6, e26359 (2011)
21. S. Kralisch, A. Tonjes, K. Krause, J. Richter, U. Lossner, P. Kovacs, T. Ebert, M. Bluher, M. Stumvoll, M. Fasshauer, Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J. Endocrinol. 216(2), 135–143 (2013)
22. R.D. Semba, K. Sun, J.M. Egan, C. Crasto, O.D. Carlson, L. Ferrucci, Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 97(4), 1375–1382 (2012)
23. C. Galman, T. Lundasen, A. Kharitonenkov, H.A. Bina, M. Eriksson, I. Hafstrom, M. Dahlin, P. Amark, B. Angelin, M. Rudling, The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8(2), 169–174 (2008)
24. Y. Shen, X. Ma, J. Zhou, X. Pan, Y. Hao, M. Zhou, Z. Lu, M. Gao, Y. Bao, W. Jia, Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc. Diabetol. 12, 124 (2013)
25. P. Lee, J. Linderman, S. Smith, R.J. Brychta, R. Perron, C. Idelson, C.D. Werner, K.Y. Chen, F.S. Celi, Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos. Int. 24(12), 3053–3057 (2013)
26. L.K. Heilbronn, L.V. Campbell, A. Xu, D. Samocha-Bonet, Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PLoS ONE 8(10), e78864 (2013)
27. A. Bisgaard, K. Sørensen, T.H. Johannsen, J.W. Helge, A.-M. Andersson, A. Juul, Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents. Int. J. Pediatr. Endocrinol. 2014, 7 (2014)
28. T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen, D.E. Moller, A. Kharitonenkov, Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12), 6018–6027 (2008)
29. J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht, R. Hecht, Y.S. Li, R.A. Lindberg, J.L. Chen, D.Y. Jung, Z. Zhang, H.J. Ko, J.K. Kim, M.M. Veniant, Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1), 250–259 (2009)